Clinical Trials

308 enrolled

Advanced Solid Tumor

NCT06265688 2026-02-20

First In Human Study of CX-2051 in Advanced Solid Tumors

160 enrolled

Solid Tumor, Adult

NCT05836324 2025-12-18

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

408 enrolled

Solid Tumors

NCT06509906 2025-12-18

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Phase 1 Terminated

3 enrolled

Phase 1 Active not recruiting

Advanced Solid Tumor

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

610 enrolled

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT06576037 2025-10-15

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

128 enrolled

Solid Tumor

NCT06336707 2024-07-18

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

1,048 enrolled

Advanced Solid Tumors

NCT02715531 2021-07-09

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

243 enrolled

Solid Tumor

NCT00786669 2021-02-10

VITAC

13 enrolled

Solid Tumor

NCT00390156 2020-07-28

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

35 enrolled

Unspecified Adult Solid Tumor

NCT02648711 2020-05-28

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Phase 1 Terminated

41 enrolled

Solid Tumors

NCT01332721 2018-12-05

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

38 enrolled 8 charts

Adult Solid Tumor

NCT00861419 2017-02-08

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

88 enrolled

Advanced Solid Tumors

NCT00416637 2016-07-07

Bevacizumab in Treating Patients With Advanced Solid Tumors

27 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT00888043 2015-03-11

CNTO95/Avastin

13 enrolled

Solid Tumors

NCT00781846 2015-02-13

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

17 enrolled

Solid Tumor

NCT00276575 2014-11-19

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

65 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT00586443 2014-11-19

BEP

56 enrolled

Solid Tumors

NCT00357318 2014-02-24

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

60 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT00085111 2013-06-05

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

24 enrolled

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00550927 2013-05-15

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

42 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT00586092 2013-04-08

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

45 enrolled

Solid Tumors

NCT00049088 2013-01-24

Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Terminated

24 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT01055795 2012-12-24

BEL

14 enrolled

Advanced Solid Tumors

NCT00005061 2012-07-18

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors

20 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT00556088 2010-12-30

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

40 enrolled